Indiplon is a pyrazolopyrimidine that acts as a high-affinity positive allosteric modulator of the GABAA receptor, potentiating GABA-activated chloride currents in a dose-dependent and reversible manner. Indiplon is selective for α1 subunits (EC50 = 2.6 nM) as compared with α2, α3, or α5 (EC50 = 24, 60, and 77 nM). Through this action, indiplon has sedative and hypnotic effects that can improve sleep onset, maintenance, and duration.
Indiplon is a member of pyrimidines with sedative, hypnotic. Indiplon has been used in trials studying the treatment of Insomnia and Depression.
ChEBI: Indiplon is a member of pyrimidines.
Potent GABA A receptor positive allosteric modulator that acts at the benzodiazepine site (K i values are 1.2 and 1.7 nM in rat frontal cortex and cerebellum respectively). Displays ~ 10-fold selectivity for α 1 subunit-containing receptors (EC 50 values are 2.6, 24, 60 and 77 nM for α 1 β 2 γ 2, α 2 β 2 γ 2, α 3 β 3 γ 2 and α 5 β 2 γ 2 receptors respectively). Exhibits sedative, hypnotic, anxiolytic and anticonvulsant activity in vivo and is orally active.
Indiplon is a novel sedative-hypnotic recently approved for the treatment of insomnia. Like other non-benzodiazepine hypnotics, its mechanism of action is to modulate subunits, especially the alpha-1 subunit, of the GABA receptor complex in order to induce sedation. Indiplon was developed in two different formulations to address two different types of insomnia complaint: indiplon-IR (immediate release) was designed for sleep onset difficulties, while indiplon-MR (modified release) was developed for sleep maintenance insomnia.
Indiplon is a nonbenzodiazepine sedative/hypnotic that is relatively new to the marketplace. It is currently undergoing clinical trials and has been under consideration by the FDA. Caldwell et al. (2009) indicated that indiplon is chemically similar in structure to zaleplon and has a half-life of approximately 1.5 h. Indiplon, which is said to work by enhancing the action of the inhibitory neurotransmitter, y-Aminobutyric acid(GABA), is like most other nonbenzodiazepine sedatives. lt is being produced in a modified release formula that will extend its half-life to aid in sleep maintenance (Ebert et al.2006).An indiplon immediate-release version targets sleep onset insomnia, whereas a modified-release form addresses sleep maintenance insomnia. Both forms of indiplon have shown improvement compared with a placebo in patients with primary insomnia in various areas of subjective and objective sleep measurements (Lankford and Ancoli-Israel 2007; Marrs 2008).Specifically, improvements in total sleep time, latency to persistent sleep,latency to sleep onset， wake after sleep onset,and sleep quality have been noted in clinical trials.So far, trials evaluating both indiplon immediate-release and modified-release have not identified any major serious adverse effects (Marrs 2008).
[1] SUSAN K SULLIVAN. Characterization of the interaction of indiplon, a novel pyrazolopyrimidine sedative-hypnotic, with the GABAA receptor.[J]. Journal of Pharmacology and Experimental Therapeutics, 2004, 311 2: 537-546. DOI:
10.1124/jpet.104.071282[2] ALAN C FOSTER. In vivo pharmacological characterization of indiplon, a novel pyrazolopyrimidine sedative-hypnotic.[J]. Journal of Pharmacology and Experimental Therapeutics, 2004, 311 2: 547-559. DOI:
10.1124/jpet.103.063487[3] MARTIN B SCHARF. Long-term nightly treatment with indiplon in adults with primary insomnia: results of a double-blind, placebo-controlled, 3-month study.[J]. Sleep, 2007, 30 6: 743-752. DOI:
10.1093/sleep/30.6.743
